3 recruiting, 2 active not recruiting, 2 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Active not recruiting 2, Withdrawn 2 |
Follow Recurrent Ovarian High Grade Serous Adenocarcinoma: new trials by email Literature Review of Recurrent Ovarian High Grade Serous Adenocarcinoma trials Research Report on Recurrent Ovarian High Grade Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection - Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 65 | 2023-12-18 | 2026-10-21 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer Abemaciclib, Biopsy Procedure, Biospecimen Collection - Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 42 | 2021-07-02 | 2026-09-11 |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents Biospecimen Collection, Cediranib Maleate, Computed Tomography - Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 120 | 2021-06-10 | 2026-10-22 |
Endometrial Neoplasms (2) · Ovarian Neoplasms (2) · Chondrosarcoma (1) · Fallopian Tube Neoplasms (1) · Melanoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3) · Genital Neoplasms, Female (3) · Neoplasms (3) · Neoplasms by Site (3) · Urogenital Diseases (3) · Urogenital Neoplasms (3) · Adnexal Diseases (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Gonadal Disorders (2) · Ovarian Diseases (2) · Uterine Diseases (2)
Magnetic Resonance Spectroscopy (5) · Specimen Handling (5) · Paclitaxel (4) · Taxes (4) · Biopsy (3) · Disulfides (3) · Immunoglobulin G (3) · olaparib (3) · Bevacizumab (2) · Doxorubicin (2) · Topotecan (2) · liposomal doxorubicin (2) · ASTX-660 (1) · Blood Component Removal (1) · Contrast Media (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)
United States (6) · Puerto Rico (1)
Camille Jackson (1) · Fiona Simpkins (1) · Jung-min Lee (1) · Kristen P Zeligs (1) · Matthew S. Block, MD, PhD (1) · Panagiotis A Konstantinopoulos (1) · Timothy A Yap, MD (1)
U10CA180868 (4), R01CA276313 (1), UM1CA186689 (1)